临床试验中复合终点分析方法的比较:Vericiguat全球研究对心力衰竭患者的见解与减少射出小部分试验
Cynthia M Westerhout1, Sarah Rathwell1, Kevin J Anstrom2
1Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
Journal of cardiac failure
|August 25, 2024
概括
韦里西瓜特通过减少住院治疗和心血管死亡,改善了心力衰竭患者的治疗结果. 新的分析方法,加权复合终点和胜利比率,证实了输送器的质量.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 维多利亚试验证明了 vericiguat在降低心力衰竭住院 (HFH) 或心血管死亡 (CVD) 的复合结果的有效性,这些患者的射出分数减少.
- 进行了二次分析,应用加权复合终点 (WCE) 和胜率 (WR) 方法,以补充对 vericiguat 的治疗效果的评估.
研究的目的:
- 通过加权复合终点 (WCE) 和胜利比率 (WR) 方法,对 vericiguat 的治疗效果进行补充评估.
- 评估WCE和WR发现与VICTORIA初级试验分析的一致性.
主要方法:
- WCE方法包括所有3412个初级临床事件,根据事件严重程度分配权重:轻度高血压 (0.39),中度高血压 (0.5),严重高血压 (0.67),和心血管疾病 (1.0).
- 在WR方法评估结果基于CVD的层次结构,其次是反复HFH.
- 这两种方法都分析了来自VICTORIA试验的数据,将 vericiguat与安慰剂进行比较.
主要成果:
- 通过WCE的方法,治疗受体的高血压调整后生存率得到了改善 (平均为78.2%与75.6%,P<.0001).
- 根据超过630万次对比的数据,WR方法表明,与 vericiguat的临床结果有所改善,WR为1.13 (P = .01),WR为6.3 (P = .01).
- 无论是WCE还是WR的结果都与初级VICTORIA试验分析一致.
结论:
- WCE和WR方法与VICTORIA初级试验分析提供一致的结果,证实了 vericiguat的益处.
- 通过包括所有反复发生的事件,考虑高血压严重程度,并提供患者体验的绝对度量,WCE方法提供了优势.
- 这些互补的评估方法可以更好地告知消费者新疗法,并指导未来的临床试验设计.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
01:12Hazard Ratio
103
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
103
01:20Imaging Studies for Cardiovascular System II:Types of Echocardiography
238
Echocardiography plays a role in assessing cardiac health and detecting heart conditions, with various types providing critical insights for diagnosis and treatment.
Types of Echocardiography
Transthoracic Echocardiography (TTE)
TTE is the most common type of echocardiogram which involves placing a transducer on the patient's chest, emitting sound waves to create heart images. TTE is invaluable for evaluating the heart's size, structure, and motion, making it particularly useful for...
Types of Echocardiography
Transthoracic Echocardiography (TTE)
TTE is the most common type of echocardiogram which involves placing a transducer on the patient's chest, emitting sound waves to create heart images. TTE is invaluable for evaluating the heart's size, structure, and motion, making it particularly useful for...
238